UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 13, 2012
KYTHERA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 001-35663 | | 03-0552903 |
| | | | |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
27200 West Agoura Road,
Calabasas, California 91301
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (818) 587-4500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 13, 2012, KYTHERA Biopharmaceuticals, Inc. issued a press release relating to its financial results for the three and nine months ended September 30, 2012. The full text of the press release is furnished herewith as Exhibit 99.1.
The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
The following Exhibit is filed as part of this Current Report on Form 8-K.
(d) Exhibits
Exhibit Number | | Description |
| | |
99.1 | | KYTHERA Biopharmaceuticals, Inc. Press Release Reporting Third Quarter 2012 Financial Results dated November 13, 2012. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: | November 13, 2012 | | KYTHERA BIOPHARMACEUTICALS, INC. |
| | | |
| | By: | |
| | | /s/ Keith R. Leonard, Jr. |
| | | Keith R. Leonard, Jr. |
| | | |
| | | President and Chief Executive Officer |
EXHIBIT INDEX
Exhibit Number | | Description |
| | |
99.1 | KYTHERA Biopharmaceuticals, Inc. Press Release Reporting Third Quarter 2012 Financial Results dated November 13, 2012. |
